| 依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察 |
| 投稿时间：2009-03-18 点此下载全文 |
| 引用本文：孙德好,邵凌,刘胜,陈森林,曹晓冰.依立替康/氟尿嘧啶/亚叶酸三药联用治疗晚期胃癌的临床疗效观察[J].药学实践杂志,2009,27(3):189~192 |
| 摘要点击次数: 937 |
| 全文下载次数: 282 |
|
|
| 中文摘要:目的:以紫杉醇/顺铂/氟尿嘧啶/亚叶酸(TAX/DDP/5-FU/LV)治疗方案为对照,探讨依立替康/氟尿嘧啶/亚叶酸(CPT-11/5-FU/LV)联合用药治疗进展期胃癌的疗效和安全性。方法:63例不能手术切除或已有转移的胃癌患者随机分为2组,治疗组:CTP-11 200 mg/d,静脉滴注2 h,第1天;LV200 mg/d,静脉滴注1 h,第1～5天;5-FU500 mg/d,静脉滴注2 h,第1～5天;对照组:TAX180 mg/d,静脉滴注2 h,第1天;DDP60 mg/d,静脉滴注1 h,第3天;LV200 mg/d,静脉滴注1 h,第1～5天;5-FU500 mg/d,静脉滴注2 h,第1～5天。两组均3周为1个周期,治疗至少2个周期,观察其有效率、生存期和毒副作用。结果:治疗组:可评价病例31例,其中CR0例,PR8例(25.8%),SD12例(38.7%),PD11例(35.5%),总有效率25.8%(8/31);对照组:可评价病例29例,其中CR0例,PR8例(27.6%),SD 12例(41.4%),PD 9例(31.0%),总有效率27.6%(8/29);两组有效率无显著性差异。治疗组和对照组中位生存期分别为7.7个月和8.3个月,1年生存率分别为34.4%和41.4%,两组比较无显著性差异。毒副作用主要为中性粒细胞下降、肝功能损伤、神经毒性、恶心、呕吐、腹泻等,多表现为Ⅰ、Ⅱ度,治疗组的腹泻发生率显著高于对照组;Ⅲ、Ⅳ度反应主要为中性粒细胞下降及神经毒性,治疗组发生率显著低于对照组。没有出现治疗相关性死亡。结论:CPT-11/5-FU/LV静滴给药是治疗进展期胃癌的有效化疗手段,毒性反应较低,但合理剂量和疗程还需进一步的大样本治疗观察。 |
| 中文关键词:依立替康 氟尿嘧啶 紫杉醇 顺铂 胃癌 化疗 |
| |
| Clinical study on combination chemotherapy with irinotecan,fluorouracil,and leucovorin in patients with advanced gastric carcinoma |
|
|
| Abstract:Objective:To investigate the efficacy and safety of irinotecan(CPT-11) plus fluorouracil(5-FU) and leucovorin(LV) in patients with advanced gastric carcinoma,in reference to those of paclitaxel(TAX) and cisplatin(DDP) combined with 5-FU and LV.Methods:63 Patients with untreated advanced gastric carcinoma were randomly enrolled into treatment group and control group.The treatment group were treated with CTP-11 200 mg on day 1,LV 200 mg and 5-FU 500 mg on day 1～5 while the control group were given TAX 180 mg on day 1,DDP 60mg on day 3,LV 200 mg and 5-FU 500 mg on day 1～5.Both regimens were repeated every 3 weeks.All the patients received at least two treatments and were evaluable for response rate,survival time,and adverse effect.Results:In 31 evaluable patients in treatment group,CR 0 case,PR 8 cases(25.8 %),SD 12 cases(38.7 %),and PD 11 cases(35.5 %).The response rate was 25.8 %(8/31).In 29 evaluable patients in control group,CR 0 case,PR 8 cases(27.6 %),SD 12 cases(41.4 %),and PD 9 cases(31.0 %).The response rate was 25.8 %(8/31).No significant difference was found in terms of response rate between two groups.The median survival and 1-year survival rates were 7.7 and 8.3 months,and 34.4 % and 41.4 % for both groups,respectively.There was no significant difference between two groups.The most common drug-related adverse effects,mainly grade Ⅰ and Ⅱ,included neutropenia,hepatic toxicity,neurotoxicity,diarrhea,nausea,and vomiting.The incidence rate of diarrhea in treatment group was significantly higher than that in control group.Adverse effects of grade Ⅲ and Ⅳ rested on neutropenia and neurotoxicity,and the incidence rate in treatment group was significantly lower than that in control group.No treatment-related death occurred.Conclusion:Intravenous drip of CPT-11/5-FU/LV seems an active approach for untreated advanced gastric carcinoma with tolerated side effects.Further extensive investigations concerning the dose and course of treatment are demand. |
| keywords:irinotecan fluorouracil paclitaxel cisplatin gastric carcinoma chemotherapy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
